Q32 Bio Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $1.2M | $3.2M | $34.0M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Operating expenses | $36.8M | $66.1M | $41.6M | $136.5M | $129.9M |
| Cash from operations | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Capital expenditure | $0 | $75,000 | $5,000 | $1.3M | $2.4M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
Shares outstanding 17.0M · Free float 39.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.